# Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM

> **NCT02780024** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 50 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02780024
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-03
- **Primary completion:** 2021-10-20
- **Final completion:** 2027-02-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02780024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02780024, "Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02780024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*